Advertisement
INTRODUCTION: Antibody drug conjugates (ADCs) are a new class of therapeutic agents, gaining increasing attention from both large and small pharmaceutical companies. Generally addressed as the marriage of an antibody with a toxic drug / chemotherapy drug, these conjugates are believed to be more efficient and effective in the treatment of a disease. The ADC market is still in its infancy. At present, Adcetris and Kadcyla are the only two marketed drugs. However, there are several ADCs under development, with most of them being developed for oncological indication. Pharmaceutical companies are keen to add innovative molecules to their diminishing product pipelines and ADCs provide an attractive opportunity due to their novel nature. Although the market now has presence of several large pharmaceutical companies, the technological capabilities for development of ADC still lies with a few technology providers. Seattle Genetics and ImmunoGen are amongst the pioneers in the field of ADC, with most pipeline ADCs using their technology. Most development to date has been carried under technology license agreements. However, we expect to see more co-development agreements in the future.
Advertisement
As more ADCs move from pipeline to the market, there is likely to be a further increase in investments in this area. Drug developers / venture capital firms are investing huge amount of money in biologics and it remains to be seen what proportion of this will be directed towards ADCs. The current market landscape will gradually evolve as large pharmaceutical companies look to gain competitive advantage in the ADC market. The future of the market is promising, though there are several challenges to meet.
SCOPE OF THE REPORT: The Antibody Drug Conjugates Market, 2014-2024 report provides an extensive study on this emerging field of therapeutics. The report covers various aspects, such as, advantages of antibody drug conjugates over traditional antibody therapeutics, the need for this new class of medicine, manufacturing challenges, key market drivers and upcoming opportunities.One of the key objectives of this report is to understand the current and future state of the antibody drug conjugates market. This is done by analysing - Products currently available in the market and those under development (both clinical / pre-clinical), - Technology providers, and key cytotoxin, linker and conjugation technologies supporting the development of improved ADCs, - Partnerships which have taken place over the last five years covering product co-development, technology licensing and co-marketing,- Competitive landscape and inherent threats to growth in the short and long term,- Development and sales potential based on target consumer segments, likely adoption rate and expected pricing.
The base year for the report is 2013; actual sales data has been presented for marketed ADCs during this year. The report provides short-mid term and long term market forecasts for the period 2014 - 2019 and 2019 - 2024, respectively. The research, analysis and insights presented in this report include potential sales of 11 marketed and pipeline ADCs; this analysis is backed by a deep understanding of key drivers behind the growth.Owing to niche nature of the market, with most products in the pipeline, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.
EXAMPLE HIGHLIGHTS: 1. Driven by the sales of Adcetris and Kadcyla (the two drugs currently available commercially), the ADC market is likely to be worth more than USD 600 million in 2014.2. About 45 molecules are currently in clinical development. Of these, approximately 25% are in Phase II or Phase III of development. As expected, the preclinical pipeline is also gradually expanding.3. Most commonly used cytotoxins for ADCs under clinical development include auristatin, calicheamicin, maytansine and duocarmycin. Auristatin dominates the market and accounts for over 50% of ADCs in clinical development.4. Roche, with 10 molecules in clinical development, has the most developed pipeline of ADCs. Relatively new entrants such as Oxford BioTherapeutics, Mersana Therapeutics, Abzena are likely to provide the necessary push (both in terms of technology and innovation).5. Seattle Genetics and ImmunoGen are the two most active companies offering their proprietary ADC technologies to a large number of ADCs under development.6. About 70%-80% of ADC manufacturing is currently outsourced. There are limited number of contract manufacturers with capabilities for development of linkers and cytotoxins. In addition, even fewer CMOs provide conjugation services for ADC.7. Several technological developments have taken place in the recent past; more stable linkers and potent cytotoxins are likely to ensure that the next generation ADCs have improved safety/efficacy profile.8. With around 7-10 new ADC commercial launches over the coming decade, we believe the overall market will be worth USD 10 billion annually by 2024.
RESEARCH METHODOLOGY
Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.The secondary sources of information include - Annual reports- Investor presentations- SEC filings- Industry databases- News releases from company websites- Government policy documents- Other analysts' opinion reportsWhile the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
CHAPTER OUTLINES: Chapter 2 presents an executive summary of the report. It offers a high level view on where the antibody drug conjugate market is headed in the mid-long term. Chapter 3 provides a general introduction to the antibody drug conjugates. In this section we have discussed, in detail, the concept of ADC, its components, mechanism of action and advantages over traditional therapies.Chapter 4 provides an overview of the ADC market. This chapter has information about all the ADC molecules in development (clinical or preclinical) along with their current phase of development, companies that are most active in the field of ADC and most common types of cytotoxin and linkers used for ADC development. Chapter 5 presents our analysis on the ADC market for the upcoming decade. It includes detailed drug profiles and likely sales forecast for each of the drug currently in phase II or higher stage of development.
Chapter 6 discusses the current manufacturing challenges associated with ADCs. It also provides information about the leading contract manufacturers which are focused in this domain. Chapter 7 provides insight to the recent developments and technological advancements. It includes a comprehensive list of partnerships, including the details of agreements, which have taken place between various pharmaceutical companies over the last few years.Chapter 8 includes profiles of the key companies in the ADC market. Each company profile includes information such as financial performance, geographical presence, marketed / pipeline ADC drugs and recent developments.Chapter 9 provides our analysis of the strengths, weaknesses, opportunities and threats in the ADC market, capturing the key elements likely to influence future growth.Chapter 10 is a collection of interview transcripts; these discussions have helped us in forming a better understanding of the key market dynamics, competitive landscape and the likely future trends in the market.Chapter 11 summarises the overall report. In this chapter, we have provided a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.
Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.Chapter 13 is an appendix, which lists down all the companies and organisations involved in the ADC market. TABLE OF CONTENTS1. PREFACE1.1. Scope of the Report1.2. Research Methodology1.3. Chapter Outlines2. EXECUTIVE SUMMARY3. INTRODUCTION3.1. Chapter Overview3.2. The Traditional Treatments: Naked Antibody and Cytotoxins3.2.1. Naked Antibodies3.2.1.1. How Monoclonal Antibody Therapy Works3.2.2. Cytotoxins3.3. Conjugated or Armed Antibodies3.4. The Revolutionary Technology: ADCs3.5. Advantages of ADC over Traditional Therapeutics3.6. Parts of an ADC3.6.1. Antibody3.6.2. Cytotoxin3.6.3. Linker: Function and Types
4. ADC THERAPEUTICS: OVERVIEW AND BACKGROUND4.1. Chapter Overview4.2. Kadcyla Becomes the Third ADC to Reach Market4.2.1. Mylotarg (Pfizer)4.2.1.1. Mechanism of Action4.2.1.2. Approval and Discontinuation of Mylotarg in the US4.2.1.3. Reasons for Poor Clinical Benefits of Mylotarg4.2.2. Adcetris (Seattle Genetics/Takeda Oncology Company)4.2.3. Kadcyla (Roche/Genentech)4.3. Companies Active in the ADC Market4.3.1. Large Pharmaceutical Companies Taking Interest4.4. Companies Providing ADC Technology4.5. Role of Venture Capitalists4.6. Analysis of the Development Pipeline4.6.1. Limited Number of Molecules in Late Stage Development4.6.2. Cancer is the Leading Indication, with ADCs Against Blood Cancer Dominating4.7. Commonly Used Cytotoxins in ADC4.7.1. Cytotoxins Used in ADCs are Highly Potent APIs4.7.2. Auristatins are the Most Commonly Used Cytotoxins4.8. Linker: Function and Types4.8.1. Manufacturing of Linkers4.8.2. ADC Market by Type of Linker
5. ADC MARKET FORECAST, 2014 - 20245.1. Chapter Overview5.2. ADC Market, 20135.2.1. Adcetris and Kadcyla were the Sole Participant in the Market in 20135.3. Overall ADC Market Forecast, 2014-20245.3.1. Scope and Limitations5.3.2. Forecast Methodology5.3.3. The ADC Drug Sales Market, 2014 - 20245.3.3.1. Overall Sales Forecast, 2014 - 2024: By Type of ADC5.3.3.2. Overall Sales Forecast, 2014 - 2024: By Type of Linker5.3.3.3. Overall Sales Forecast, 2014 - 2024: By Type of Cytotoxin5.4. Adcetris (Seattle Genetics / Millennium)5.4.1. Mechanism of Action5.4.2. The Cost of Treatment with Adcetris and Reimbursement5.4.3. Factors Supporting the High Price5.4.4. Adcetris Sales, 2011-Q1 20145.4.5. Strategies for Market Expansion5.4.6. Adcetris Sales Forecast: Short-Mid Term, 2014-20195.4.7. Adcetris Sales Forecast: Long Term, 2019-2024
5.5. Kadcyla / T-DM1 (Genentech / Roche)5.5.1. Drug Specifications5.5.2. Launch and Reimbursement5.5.3. Pricing5.5.4. Roche's Survival Kit5.5.5. Long Route to Approval5.5.6. Kadcyla Sales5.5.7. Current State of Development: Indications and Timeline5.5.8. Kadcyla Sales Forecast, 2014-20195.5.9. Kadcyla Sales Forecast: Long Term, 2019-20245.6. Glembatumumab Vedotin / CDX-011 (Celldex Therapeutics)5.6.1. The Drug Specifications5.6.2. Clinical Development5.6.2.1. Metric Trial5.6.3. Competition for CDX-0115.6.4. CDX-011 Sales Forecast, 2014-20195.6.5. CDX-011 Sales Forecast: Long Term, 2019-2024
5.7. BT-062 (Biotest)5.7.1. Drug Specifications5.7.2. Clinical Development5.7.3. Competition for Bt-0625.7.4. BT-062 Sales Forecast: Short-Mid Term, 2017-20195.7.5. BT-062 Sales Forecast: Long Term, 2019-20245.8. Inotuzumab Ozogamicin/CMC-544 (Pfizer)5.8.1. Drug Specifications5.8.2. Current Development Status5.8.3. Competition for CMC-5445.8.4. Inotuzumab Ozogamicin / CMC-544 Sales Forecast: Long Term, 2018-20245.9. RG7593 and RG7596 (Roche)5.9.1. Drug Specifications5.9.2. Clinical Development5.9.3. Future Plans5.9.4. RG7596 Sales Forecast: Long Term, 2018-20245.10. PSMA-ADC (Progenics)5.10.1. Drug Specifications5.10.2. PSMA ADC Development for Prostate Cancer5.10.3. Competition for PSMA ADC5.10.4. PSMA ADC Sales Forecast: Long Term, 2019-2024
5.11. SAR3419 (Sanofi Aventis)5.11.1. Drug Specifications5.11.2. Structure, Administration and Dosage5.11.3. Current State of Development5.11.4. Competition for SAR34195.11.5. SAR3419 Sales Forecast: Long Term, 2019-20245.12. IMMU-130 (Immunomedics)5.12.1. Drug Specifications5.12.2. Clinical Development5.12.3. Competition for IMMU-1305.12.4. IMMU-130 Sales Forecast: Long Term, 2019-20245.13. RG7599 (Roche / Genentech)5.13.1. Drug Specifications5.13.2. Clinical Trial and Development5.13.3. Competition For RG75995.13.4. RG7599 Sales Forecast: Long Term, 2020-2024
5.14. ABT-414 (AbbVie)5.14.1. Drug Specifications5.14.2. Clinical Trials and Development5.14.3. Competition for ABT-4145.14.4. ABT-414 Sales Forecast: Long Term, 2020-20246. MANUFACTURING OF ADCs6.1. Chapter Overview6.2. Steps Involved in Manufacturing an ADC6.3. Challenges Facing the ADC Manufacturers6.4. In-House Manufacturing of ADCs6.5. Presence of Contract Manufacturers6.5.1. Linkers6.5.2. Cytotoxins6.5.3. Conjugation6.6. Leading ADC Contract Manufacturers6.6.1. SAFC6.6.2. Piramal Healthcare6.6.3. Lonza6.6.4. Albany Molecular Research Institute (AMRI)6.6.5. BSP Pharmaceuticals6.6.6. Pierre Fabre Medicament Production (PFMP)6.6.7. Catalent6.7. CMOs Investing in ADC Capabilities6.8. Contract Manufacturers Collaborating to Provide ADC Capabilities
7. RECENT DEVELOPMENTS: FOCUS ON PARTNERSHIPS AND TECHNOLOGY EVOLUTION7.1. Chapter Overview7.2. Recent Partnerships7.2.1. Partnership Models7.2.2. Number of Partnerships have Increased Overtime7.2.3. Seattle Genetics and ImmunoGen have been the Most Active Companies7.3. Technological Developments7.3.1. Emerging Cytotoxins/Payload7.3.2. Linker Technologies7.3.3. Site-Specific Conjugation Technology7.3.4. Use of Antibody Fragments in Place of Whole Antibody8. PROFILES OF LEADING COMPANIES
8.1. Chapter Overview8.2. ImmunoGen8.2.1. Targeted Antibody Payload (TAP) Technology8.2.1.1. Linker Technology8.2.2. Marketed and Pipeline Products8.2.2.1. Marketed ADCs8.2.2.2. Pipeline ADCs8.2.3. Business Model8.2.3.1. Types of Agreements and Current Partners8.2.4. In-House Manufacturing Capabilities8.2.5. Financial Performance8.3. Seattle Genetics8.3.1. ADC Technology8.3.2. Exploring New Technologies8.3.2.1. Novel Cytotoxins8.3.2.2. Site-Specific Conjugation Technology8.3.3. Business Model8.3.3.1. Types of Agreements and Current Partners8.3.4. Marketed and Pipeline Products8.3.4.1. Marketed ADCs8.3.4.2. Pipeline ADCs8.3.5. Financial Performance
8.4. Immunomedics8.4.1. Marketed and Pipeline Products8.4.2. Financial Performance8.5. Spirogen (Acquired by MedImmune)8.5.1. Pyrrolobenzodiazepines (PBDs) Technology8.5.2. ADC Development and Collaborations8.5.3. AstraZeneca Takes Over Spirogen8.6. Pfizer8.6.1. Marketed and Pipeline Products8.6.2. Collaboration with Seattle Genetics8.6.3. Financial Performance8.7. Roche/Genentech8.7.1. Evaluating Technology from ImmunoGen and Seattle Genetics8.7.2. Development Pipeline: 10 Molecules in Clinical Development8.7.3. Financial Performance8.8. Polytherics (An Abzena Company)8.8.1. ThioBridge Technology8.8.2. Pegylation and Optimisation Technology8.8.3. Business Model8.8.4. Revenue Generation8.9. Oxford BioTherapeutics8.9.1. Oxford Genome Anatomy Project8.9.2. ADC Pipeline8.10. Other Companies8.10.1. Mersana Therapeutics8.10.1.1. Fleximer- ADC Technology8.10.1.2. ADC Collaborations8.10.1.3. Funding
8.10.2. Synthon8.10.2.1. ADC Technology8.10.2.2. ADC Manufacturing8.10.2.3. ADC Pipeline8.10.3. Intellect Neurosciences8.10.3.1. CONJUMAB-A Technology8.10.3.2. ADC Pipeline8.10.3.3. Financial Performance8.10.4. Progenics Pharmaceuticals8.10.4.1. PSMA Targeted Oncology Pipeline8.10.4.2. Financial Performance8.10.5. Astellas Pharma/Agensys8.10.5.1. ADC Pipeline8.10.5.2. Financial Performance8.10.6. Heidelberg Pharma8.10.6.1. ADC Technology8.10.6.2. ADC Pipeline9. SWOT ANALYSIS9.1. Strengths9.2. Weaknesses9.3. Opportunities9.4. Threats
10. INTERVIEW TRANSCRIPTS10.1. Interview 1: Lonza, Laurent Ducry, ADC R&D10.2. Interview 2: Polytherics (an Abzena company), Dr. John Burt, CEO, Abzena10.3. Interview 3: Oxford BioTherapeutics, Dr. Christian Rohlff, Founder and CEO10.4. Interview 4: Catalent Pharma Solutions, Stacy McDonald, Group Product Manager & Jennifer L. Mitcham, Director - Business Development10.5. Interview 5: BSP Pharmaceuticals, Aldo Braca, CEO10.6. Interview 6: Piramal Healthcare, Dr. Mark Wright, Site Head, Grangemouth10.7. Interview 7: Leading CMO, Director, Business Development11. CONCLUSIONS11.1. ADC: Expanding the Pipeline of Biologics11.2. Market is in its Infancy, with Huge Potential for Growth11.3. CMOs: Narrowing the Need Supply Gap11.4. An Attractive Market for Large Pharmaceutical Companies11.5. Concluding Remarks12. APPENDIX 1: TABLES13. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS
?LIST OF FIGURESFigure 2.1 ADC Clinical Trials: Market MapFigure 3.1 Parts of Antibody Drug ConjugateFigure 4.1 Companies Active in the ADC Market: Number of Molecules in Development (Clinical and Marketed)Figure 4.2 ADCs in Clinical Development: Share (%) by Phase of DevelopmentFigure 5.1 ADC Sales Forecast, 2014 - 2024: Base Scenario (USD Million)Figure 5.2 ADC Sales Forecast, 2014 - 2024: By Type of ADC (USD Million)Figure 5.3 ADC Sales Forecast, 2014 - 2024: By Type of Linker (USD Million)Figure 5.4 ADC Sales Forecast, 2014 - 2024: By Type of Cytotoxin (USD Million)Figure 5.5 Adcetris Sales, 2011-Q1 2014 (USD Million)Figure 5.6 Adcetris Market (USD Million), Short-Midterm Forecast: 2014-2019 (Base Scenario)Figure 5.7 Adcetris Market (USD Million), Long Term Forecast: 2019-2024 (Base Scenario)Figure 5.8 Kadcyla Sales, 2013 – 2014 (USD Million)Figure 5.9 Kadcyla / T-DM1 Market (USD Million), Short-Midterm Forecast: 2014-2019 (Base Scenario)Figure 5.10 Kadcyla / T-DM1 Market (USD Million), Long Term Forecast: 2019-2024 (Base Scenario)Figure 5.11 Glembatumumab Vedotin / CDX-011 Market (USD Million), Short-Midterm Forecast: 2017-2019 (Base Scenario)Figure 5.12 Glembatumumab Vedotin / CDX-011 Market (USD Million), Long Term Forecast: 2019-2024(Base Scenario)Figure 5.13 BT-062 Market (USD Million), Short-Midterm Forecast, 2017-2019 (Base Scenario)Figure 5.14 BT-062 Market (USD Million), Long Term Forecast, 2019-2024 (Base Scenario)Figure 5.15 Inotuzumab Ozogamicin / CMC-544 Market (USD Million), Long Term Forecast: 2018-2024 (Base Scenario)Figure 5.16 RG7596 Market (USD Million), Long Term Forecast, 2018-2024 (Base Scenario)Figure 5.17 PSMA ADC Market (USD Million), Long Term Forecast, 2019-2024 (Base Scenario)Figure 5.18 SAR3419 Market (USD Million), Long Term Forecast, 2019-2024 (Base Scenario)Figure 5.19 IMMU-130Market (USD Million), Long Term Forecast, 2018-2024 (Base Scenario)Figure 5.20 RG7599 Market (USD Million), Long Term Forecast, 2018-2024 (Base Scenario)Figure 5.21 ABT-414 Market (USD Million), Long Term Forecast, 2018-2024 (Base Scenario)Figure 7.1 Number of Partnerships in the Field of ADCs, 2005 - 2014Figure 7.2 ADC Partnerships: Major StakeholdersFigure 8.1 Seattle Genetics: Sales Performance (USD Million), 2011-2014 Q1Figure 8.2 Pfizer Sales Performance (USD Billion), 2011 – 2014 Q1Figure 8.3 Roche Group Sales Performance (CHF Billion), 2011 – 2014 Q1Figure 8.4 Roche Group HER2 Franchise Sales Performance (CHF million), 2013 - 2014 Q1Figure 11.1 ADC Market (USD Million) Forecast: 2014, 2019 and 2024
?LIST OF TABLESTable 3.1 Commonly Used Cytotoxins for ADC TherapeuticsTable 4.1 Approval History of MylotargTable 4.2 ADC Molecules in Clinical Development: Roche / GenentechTable 4.3 ADC Molecules in Clinical Development: Seattle GeneticsTable 4.4 ADC Molecules in Clinical Development: ImmunoGenTable 4.5 ADC Molecules in Clinical Development: ImmunomedicsTable 4.6 ADC Molecules in Clinical Development: Astellas Pharma / AgensysTable 4.7 ADC Molecules in Clinical Development: Pfizer / WyethTable 4.8 ADC Molecules in Clinical Development: Sanofi AventisTable 4.9 ADC Molecules in Clinical Development: AmgenTable 4.10 ADC Molecules in Clinical Development: AbbVieTable 4.11 ADC Molecules in Clinical Development: MillenniumTable 4.12 ADC Molecules in Clinical Development: Celldex TherapeuticsTable 4.13 ADC Molecules in Clinical Development: Progenics PharmaceuticalsTable 4.14 ADC Molecules in Clinical Development: GenmabTable 4.15 ADC Molecules in Clinical Development: Bayer HealthcareTable 4.16 ADC Molecules in Clinical Development: BiotestTable 4.17 ADC Molecules in Clinical Development: Bristol-Myers SquibbTable 4.18 ADC Molecules in Clinical Development: Stem CentRxTable 4.19 ADC Molecules in Clinical Development: VIVENTIA BiotechnologiesTable 4.20 ADC Molecules in Preclinical Development: AmbrxTable 4.21 ADC Molecules in Preclinical Development: Oxford BioTherapeuticsTable 4.22 ADC Molecules in Preclinical Development: Novartis
Table 4.23 ADC Molecules in Preclinical Development: Roche / GenentechTable 4.24 ADC Molecules in Preclinical Development: Sanofi AventisTable 4.25 ADC Molecules in Preclinical Development: AmgenTable 4.26 ADC Molecules in Preclinical Development: SynthonTable 4.27 ADC Molecules in Preclinical Development: AbbVieTable 4.28 ADC Molecules in Preclinical Development: AbGenomicsTable 4.29 ADC Molecules in Preclinical Development: ADC TherapeuticsTable 4.30 ADC Molecules in Preclinical Development: AffiniconTable 4.31 ADC Molecules in Preclinical Development: AllozyneTable 4.32 ADC Molecules in Preclinical Development: Avid BiologicsTable 4.33 ADC Molecules in Preclinical Development: Astellas / AgensysTable 4.34 ADC Molecules in Preclinical Development: BayerTable 4.35 ADC Molecules in Preclinical Development: Bristol Myers SquibbTable 4.36 ADC Molecules in Preclinical Development: Celldex TherapeuticsTable 4.37 ADC Molecules in Preclinical Development: Daiichi SankyoTable 4.38 ADC Molecules in Preclinical Development: Eli LillyTable 4.39 ADC Molecules in Preclinical Development: Endo PharmaceuticalsTable 4.40 ADC Molecules in Preclinical Development: Esperance PharmaceuticalsTable 4.41 ADC Molecules in Preclinical Development: GSKTable 4.42 ADC Molecules in Preclinical Development: Intellect NeurosciencesTable 4.43 ADC Molecules in Preclinical Development: MerckTable 4.44 ADC Molecules in Preclinical Development: ImmunoGenTable 4.45 ADC Molecules in Preclinical Development: Heidelberg PharmaTable 4.46 ADC Molecules in Preclinical Development: Seattle GeneticsTable 4.47 ADC Molecules in Preclinical Development: National Research Council, CanadaTable 4.48 ADC Molecules in Preclinical Development: PfizerTable 4.49 ADC Molecules in Preclinical Development: PhilochemTable 4.50 ADC Molecules in Preclinical Development: CytomX TherapeuticsTable 4.51 Commonly Used Cytotoxins for ADC TherapeuticsTable 4.52 OEL Bands, Safebridge Consultants
Table 4.53 Pipeline ADCs Using Valine-Citrulline Peptide LinkerTable 4.54 Pipeline ADCs Using Hindered Disulphide LinkerTable 4.55 Pipeline ADCs Using Hydrazone LinkerTable 4.56 Pipeline ADCs Using Maleimidocaproyl LinkerTable 4.57 Pipeline ADCs Using Thioether LinkerTable 4.58 Pipeline ADCs Using Protease Cleavable Peptide LinkerTable 4.59 Pipeline ADCs Using Other Non-Cleavable LinkerTable 4.60 Pipeline ADCs Using Furin Cleavable Peptide LinkerTable 5.1 Current Development Phase and Expected Launch Year of ADCs in Clinical Development (Phase II and Higher)Table 5.2 Adcetris: Ongoing Clinical TrialsTable 5.3 List of Trastuzumab Biosimilars Under Development, 2014Table 5.4 Kadcyla / T-DM1: Ongoing Clinical TrialsTable 5.5 BT-062: Ongoing Clinical TrialsTable 5.6 Inotuzumab Ozogamicin/CMC-544: Ongoing Clinical TrialsTable 5.7 Comparison of Drugs Available for Metastatic Castration Resistant Prostate CancerTable 5.8 SAR3419: Ongoing Clinical TrialsTable 5.9 IMMU-130: Ongoing Clinical TrialsTable 5.10 RG7599: Ongoing Clinical TrialsTable 5.11 ABT-414: Ongoing Clinical TrialsTable 6.1 List of Contract Manufacturers and Their Capabilities in ADC ManufacturingTable 7.1 List of Partnerships in the Field of ADCs, 2000 - 2014Table 7.2 Companies Providing Site-Specific Conjugation TechnologyTable 8.1 ImmunoGen ADC Pipeline, 2014Table 8.2 Seattle Genetics ADC Pipeline, 2014Table 8.3 Immunomedics ADC Pipeline, 2014Table 8.4 Pfizer / Wyeth ADC Pipeline, 2014Table 8.5 Roche / Genentech ADC Pipeline, 2014
Table 8.6 Oxford BioTherapeutics ADC Pipeline, 2014Table 8.7 Synthon ADC Pipeline, 2014Table 8.8 Intellect Neurosciences ADC Pipeline, 2014Table 8.9 Progenics Pharmaceuticals PSMA Pipeline, 2014Table 8.10 Astellas Pharma / Agensys ADC Pipeline, 2014Table 9.1 SWOT Analysis of ADC MarketTable 12.1 ADCs in Clinical Development: Share (%) by Phase of DevelopmentTable 12.2 ADC Sales Forecast 2014 - 2024: Base Scenario (USD Million)Table 12.3 ADC Sales Forecast, 2014 - 2024: Conservative Scenario (USD Million)Table 12.4 ADC Sales Forecast, 2014 - 2024: Optimistic Scenario (USD Million)Table 12.5 ADC Sales Forecast, 2014 - 2024: By Type of Linker (USD Million)Table 12.6 ADC Sales Forecast, 2014 - 2024: By Type of Cytotoxin (USD Million)Table 12.7 Adcetris Sales, 2011-Q1 2014 (USD Million)Table 12.8 Adcetris Market (USD Million), Short-Midterm Forecast: 2014-2019 (Base Scenario)Table 12.9 Adcetris Market (USD Million), Short-Midterm Forecast: 2014-2019 (Conservative Scenario)Table 12.10 Adcetris Market (USD Million), Short-Midterm Forecast: 2014-2019 (Optimistic Scenario)Table 12.11 Adcetris Market (USD Million), Long Term Forecast: 2019-2024 (Base Scenario)Table 12.12 Adcetris Market (USD Million), Long Term Forecast: 2019-2024 (Conservative Scenario)Table 12.13 Adcetris Market (USD Million), Long Term Forecast: 2019-2024 (Optimistic Scenario)Table 12.14 Kadcyla / T-DM1 Market (USD Million), Short-Midterm Forecast: 2014-2019 (Base Scenario)Table 12.15 Kadcyla / T-DM1 Market (USD Million), Short-Midterm Forecast: 2014-2019 (Conservative Scenario)Table 12.16 Kadcyla / T-DM1 Market (USD Million), Short-Midterm Forecast: 2014-2019 (Optimistic Scenario)Table 12.17 Kadcyla / T-DM1 Market (USD Million), Long Term Forecast: 2019-2024 (Base Scenario)Table 12.18 Kadcyla / T-DM1 Market (USD Million), Long Term Forecast: 2019-2024 (Conservative Scenario)Table 12.19 Kadcyla / T-DM1 Market (USD Million), Long Term Forecast: 2019-2024 (Optimistic Scenario)
Table 12.20 Glembatumumab Vedotin / CDX-011 Market (USD Million), Short-Midterm Forecast: 2016-2019 (Base Scenario)Table 12.21 Glembatumumab Vedotin / CDX-011 Market (USD Million), Short-Midterm Forecast: 2016-2019 (Conservative Scenario)Table 12.22 Glembatumumab Vedotin / CDX-011 Market (USD Million), Short-Midterm Forecast: 2016-2019 (Optimistic Scenario)Table 12.23 Glembatumumab Vedotin / CDX-011 Market (USD Million), Long Term Forecast: 2019-2024 (Base Scenario)Table 12.24 Glembatumumab Vedotin / CDX-011 Market (USD Million), Long Term Forecast: 2019-2024 (Conservative Scenario)Table 12.25 Glembatumumab Vedotin / CDX-011 Market (USD Million), Long Term Forecast: 2019-2024 (Optimistic Scenario)Table 12.26 BT-062 Market (USD Million), Short-Midterm Forecast, 2017-2019 (Base Scenario)Table 12.27 BT-062 Market (USD Million), Short-Midterm Forecast, 2017-2019 (Conservative Scenario)Table 12.28 BT-062 Market (USD Million), Short-Midterm Forecast, 2017-2019 (Optimistic Scenario)Table 12.29 BT-062 Market (USD Million), Long Term Forecast, 2019-2024 (Base Scenario)Table 12.30 BT-062 Market (USD Million), Long Term Forecast, 2019-2024 (Conservative Scenario)Table 12.31 BT-062 Market (USD Million), Long Term Forecast, 2019-2024 (Optimistic Scenario)Table 12.32 Inotuzumab Ozogamicin / CMC-544 Market (USD Million), Long Term Forecast: 2018-2024 (Base Scenario)Table 12.33 Inotuzumab Ozogamicin / CMC-544 Market (USD Million), Long Term Forecast: 2018-2024 (Conservative Scenario)Table 12.34 Inotuzumab Ozogamicin / CMC-544 Market (USD Million), Long Term Forecast: 2018-2024 (Optimistic Scenario)Table 12.35 RG7596 Market (USD Million), Long Term Forecast, 2018-2024 (Base Scenario)Table 12.36 RG7596 Market (USD Million), Long Term Forecast, 2018-2024 (Conservative Scenario)
Table 12.37 RG7596 Market (USD Million), Long Term Forecast, 2018-2024 (Optimistic Scenario)Table 12.38 PSMA ADC Market (USD Million), Long Term Forecast, 2019-2024 (Base Scenario)Table 12.39 PSMA ADC Market (USD Million), Long Term Forecast, 2019-2024 (Conservative Scenario)Table 12.40 PSMA ADC Market (USD Million), Long Term Forecast, 2019-2024 (Optimistic Scenario)Table 12.41 SAR3419 Market (USD Million), Long Term Forecast, 2019-2024 (Base Scenario)Table 12.42 SAR3419 Market (USD Million), Long Term Forecast, 2019-2024 (Conservative Scenario)Table 12.43 SAR3419 Market (USD Million), Long Term Forecast, 2019-2024 (Optimistic Scenario)Table 12.44 IMMU-130 Market (USD Million), Long Term Forecast, 2018-2024 (Base Scenario)Table 12.45 IMMU-130 Market (USD Million), Long Term Forecast, 2018-2024 (Conservative Scenario)Table 12.46 IMMU-130 Market (USD Million), Long Term Forecast, 2018-2024 (Optimistic Scenario)Table 12.47 RG7599 Market (USD Million), Long Term Forecast, 2018-2024 (Base Scenario)Table 12.48 RG7599 Market (USD Million), Long Term Forecast, 2018-2024 (Conservative Scenario)Table 12.49 RG7599 Market (USD Million), Long Term Forecast, 2018-2024 (Optimistic Scenario)Table 12.50 ABT-414 Market (USD Million), Long Term Forecast, 2018-2024 (Base Scenario)Table 12.51 ABT-414 Market (USD Million), Long Term Forecast, 2018-2024 (Conservative Scenario)Table 12.52 ABT-414 Market (USD Million), Long Term Forecast, 2018-2024 (Optimistic Scenario)Table 12.53 Seattle Genetics: Sales Performance (USD Million), 2011-2014 Q1Table 12.54 Pfizer Sales Performance (USD Billion), 2011 – 2014 Q1Table 12.55 Roche Group Sales Performance (CHF Billion), 2011 – 2014 Q1Table 12.56 Roche Group HER2 Franchise Sales Performance (CHF Million), 2013 – 2014 Q1
To order this report: Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html
__________________________Contact Clare: [email protected] US: (339)-368-6001Intl: +1 339-368-6001
SOURCE Reportlinker
